Skip to main content
Premium Trial:

Request an Annual Quote

Gary Kruppa, Gail Page, Martin Verhoef, Stephen Blose, Daniel Bradbury


Gary Kruppa will join Bruker Daltonics of Billerica, Mass., as vice president for western US operations next month. He will be based in Fremont, Calif. Kruppa joins Bruker from Sandia National Laboratories, where he studied the three-dimensional structures of proteins using mass spec. Prior to that, he worked for Bruker Daltonics and Bruker Instruments. Before joining Bruker, he was a research scientist at Ciba-Geigy. Kruppa holds a BS from the University of Delaware and a PhD in chemical physics from Caltech.

Gail Page has become president of Ciphergen Biosystems’ new Diagnostics Division, and executive vice president of Ciphergen; while Martin Verhoef has been promoted to president of Ciphergen Biosystems, Division, a new business unit, and to executive vice president of Ciphergen. Page comes to Ciphergen from Luminex, where she was executive vice president and chief operating officer between 2000 and 2003. Prior to that, Page served in various management roles at Laboratory Corporation of America, which she joined in 1988. She received a medical technology degree and an AS degree in cardiopulmonary technology from the University of Florida. Verhoef joined the company in April 2000, and most recently held the position of senior vice president, sales, marketing, and operations. Prior to joining Ciphergen, he worked in Agilent Technologies’ DNA microarray business, and prior to that, in their liquid chromatography division. He initially worked at Pharmacia LKB Biotechnology in the Netherlands and in Sweden. Verhoef holds a BS in medical microbiology and biochemistry from the Van’t Hoff Institute in Rotterdam, the Netherlands.

Stephen Blose has been appointed to the board of directors at BioMicro Systems of Salt Lake City. He previously served as division general manager of imaging products at Bio-Rad Laboratories, and prior to that, as CEO of Protein Databases, a service provider in proteomics. Earlier, he was a senior scientist at Cold Spring Harbor Laboratory.

Daniel Bradbury has joined the board of directors of Illumina of San Diego, the company said this week. He is currently COO of Amylin Pharmaceuticals. He holds a pharmacy degree from Nottingham University, UK, and a diploma in management studies from Harrow and Ealing Colleges of Higher Education.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.